Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. (Q53534282)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 2000

Language	Label	Description	Also known as
English	Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure.	scientific article published in January 2000

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

0 references

1 reference

based on heuristic

inferred from title

chronic heart failure

1 reference

based on heuristic

inferred from title

2

object named as

R M Califf

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

author name string

M S Cuffe

1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

K F Adams

3

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

R C Bourge

4

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

W Colucci

5

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

B Massie

6

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

C M O'Connor

7

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

I Pina

8

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

R Quigg

9

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

M Silver

10

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

L A Robinson

11

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

J D Leimberger

12

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

M Gheorghiade

13

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

language of work or name

0 references

publication date

1 January 2000

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

139

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

1 Pt 1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

15-22

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

The epidemiology of heart failure: the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Prevalence and mortality rate of congestive heart failure in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Effect of DRGs on three-month readmission rate of geriatric patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Early readmission of elderly patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Medical conditions differentially affect the development of IADL disability: implications for medical care and research

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Milrinone: basic and clinical pharmacology and acute and chronic management

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Phosphodiesterase III inhibition or adrenoreceptor stimulation: Milrinone as an alternative to dobutamine in the treatment of severe heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Current medical therapy for advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Reporting Bayesian analyses of clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

The hibernating myocardium: implications for management of congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990303-X

7 January 2021

Identifiers

10.1016/S0002-8703(00)90303-X

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/10618557

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53534282&oldid=2212882323"